As a further test of lectins' applicability against coronaviruses in general, and translation to inhibition of fully infectious virus, plaque reduction assays were also performed with CV-N treatment against fully infectious murine coronavirus (MHV-A59) (Figure ). The data showed that CV-N inhibits infection of fully infectious murine coronavirus, suggesting a pan-coronavirus potential for lectin inactivation.